On October 31, 2023, Selecta Biosciences Inc. and Swedish Orphan Biovitrum AB (publ.) entered into Amendment No. 1 to the License and Development Agreement by and between the Company and Sobi. Pursuant to the Amendment, the Company granted Sobi an exclusive license to manufacture ImmTOR solely in connection with Sobi?s development of SEL-212 under the Agreement and is transferring certain contracts and manufacturing equipment to Sobi.

Additionally, in connection with entry into the Amendment, Sobi agreed to make employment offers to certain of the Company?s employees engaged in ImmTOR manufacturing activities on or prior to a specified date, and the Company agreed not to terminate the employment of such employees prior to such specified date. As a result of the Amendment, the Company maintains no responsibilities to Sobi to manufacture, or supply Sobi with, ImmTOR under the Agreement.